Aim: Human exposure to organic pollutants (some of them also called endocrine disruptors) can be associated with adverse metabolic health outcomes including type 2 diabetes. The aim of this study was to compare the urine levels of bisphenol A and phthalate metabolites in subgroups of patients with metabolic syndrome composed of patients with and without three important components of metabolic syndrome (hypertension, dyslipidemia and diabetes).
INTRODUCTION
Human exposure to organic pollutants (some of them also called endocrine disruptors) may be associated with a risk of metabolic syndrome and type 2 diabetes (1-4). The molecular mechanisms involved are still largely unknown, but alteration of gene expression after binding to the aryl hydrocarbon receptor (AhR), peroxisome proliferator-activated receptor (PPAR), and estrogen receptors seems to play a role. The interaction between endocrine disruptors exposure and nuclear polymorphisms associated with obesity, type 2 diabetes, and cardiovascular disease is important (5) . Longitudinal studies have found a long-term risk of type 2 diabetes and hypertension (6) .
In the present study, we evaluated actual urinary levels of some organic pollutants (phthalates and bisphenol A) in relation to hypertension, dyslipidemia, and type 2 diabetes as well as to age and BMI, all related to metabolic syndrome. The study was conducted on a group of patients from the Metabolic Outpatient Department of University Hospital in Prague. The aim of this study was to compare the urine level of bisphenol A and phthalates in subgroups of patients with metabolic syndrome and patients with and without three important components of metabolic syndrome (hypertension, dyslipidemia and diabetes).
MATERIAL AND METHODS
One hundred and sixty-eight patients with metabolic syndrome were included in the present study (57 males and 111 females). The mean age of our patients was 51.2 and 65 years for males and females, respectively. Basic characteristics of patients stratified to diabetics and non-diabetics are shown in Table 1 .
Urinary phthalates and bisphenol A/creatinine ratio was analyzed in those who were coming consecutively to the Metabolic Outpatient Department, 3rd Department of Medicine, Prague. Patients were classified as dyslipidemic (n = 87), hypertensive (n = 96), and with type 2 diabetes (n = 58) according to metabolic syndrome criteria (7) and/or according to used pharmacotherapy. Phthalate metabolite levels were compared in patients with and without dyslipidemia, with and without hypertension, and with and without diabetes.
Fifteen different phthalate metabolites (Table 2) were analyzed in urine: mono-(3-carboxypropyl) phthalate (MCPP), monoethyl phthalate (MEP), monoisobuthyl phthalate (MiBP), mono-nbuthyl phthalate (MnBP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (OH-MEHP), mono-(2-ethyl-5-oxohexyl) phthalate (OXO-MEHP), mono-(2-ethyl-5-carboxypentyl) phthalate (cx-MEHP), monobenzyl phthalate (MBzP), mono-(4-methyl-7-oxo-octyl) phthalate (OXO-MMeOP), mono-(4-methyl-7-hydroxyoctyl) phthalate (OH-MMeOP), mono-(4-methyl-7-carboxyheptyl) phthalate (cx-MMeHP), mono-(2-propyl-6-carboxyhexyl) phthalate (cx-MPHxP), mono-(2-propyl-6-hydroxyheptyl) phthalate (OH-MPHP), mono-(2-propyl-6-oxo-heptyl) phthalate (OXO-MPHP), and mono-(2-ethylhexyl) phthalate (MEHP).
Metabolites were analyzed with enzymatic cleavage of glucuronide using ultra-high-performance liquid chromatographyelectrospray ionization tandem mass spectrometry in one laboratory with external quality control. Detailed description of the analytic procedures was presented in the work of Vrbík et al. (8) . For seven metabolites (MCPP, MBzP, cx-MMeHP, cx-MPHxP, OH-MPHP, OXO-MPHP, MEHP) more than 50% of values were less than the limit of quantification. These metabolites were not used for further comparisons. Creatinine-adjusted urinary concentrations (micrograms per gram creatinine) were analyzed. Great variability and asymmetrical distribution were seen in phthalate metabolites and bisphenol A levels. The location and variability of the data is characterized by median and interquartile range. Group comparisons were performed using non-parametric MannWhitney test. Diabetes, hypertension, dyslipidemia, age, and BMI were evaluated as possible predictors of metabolite levels by multiple linear regression applied to logarithm of phthalate metabolite. All statistical tests were evaluated at a significance level of 0.05. Data were analyzed using statistical software Stata, release 9.2 (Stata Corp LP, College Station, TX).
RESULTS

Diabetes Type 2 Patients
Characteristics of creatinine-adjusted concentrations of selected metabolites (expressed as µg/g) are shown in Table  3 . Four metabolites (mono-n-butyl phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and mono-(2-ethyl-5-carboxypentyl) phthalate) had significantly higher levels in type 2 diabetic in comparison to non-diabetic patients. There was no significant difference in the other four analyzed phthalate metabolites and in bisphenol A levels between patients with and without diabetes.
Hypertensive and Dyslipidemic Patients
There was no significant difference in any analyzed phthalate metabolite or in bisphenol A levels when comparing patients with and without hypertension and dyslipidemia.
Age and BMI
Multiple linear regression with five explanatory variables including age, BMI, diabetes type 2, hypertension, and dyslipidemia showed that diabetes type 2 remains statistically significant predictor of four phthalates (MnBP, OH-MEHP, OXO-MEHP, and cx-MEHP) even after adjustment to four other variables included in the model. None of these variables was significant and so metabolite levels were substantially determined only by diabetes.
DISCUSSION
Phthalate exposure is related to many diseases including metabolic and cardiovascular diseases, cancer, allergy, developmental 
. Phthalate exposure results mostly from plasticizers (substances added to plastics to increase their flexibility and longevity). They are mostly used for softening polyvinyl chloride (PVC). To the organism phthalates can come through food (mostly canned or in plastics packaging), through air pollution including home dust, and also from many skin care products (10, 11) . In a previous study, urine phthalate excretion correlated well with the use of plastic packaging and skin care (12) . However, use of phthalates in plasticizers has been significantly reduced and today mostly non-phthalate plasticizers are used (13) . Bisphenol A is an estrogenic compound and is coming to the body from plastics (14) and thermal print paper (15) . Several clinical studies show that humans exposed to bisphenol A are more likely to incur reproductive disorders like reduction of spermatogenesis, decreased testosterone production or malformation of the genitals or induction of tumors like mammary carcinoma, immune function and allergy, obesity and diabetes (4, 16) . Bisphenol A, a common and widely utilized chemical contaminant acting as endocrine disruptor, accumulates in adipose tissue and may affect adipocyte metabolic and inflammatory functions. At low chronic doses it is now considered an obesogen compound and it might contribute to the rise of metabolic syndrome, visceral adiposity and diabetes epidemics. Bisphenol A is present in the environment worldwide and it is responsible for chronic exposure during vulnerable periods, such as foetal and neonatal life. The source of contamination can occur via food, beverage, wastewater, air, dust, and soil. Bisphenol A, as lipophilic compound, may accumulate into the adipose tissue already during foetal life and may affect adulthood health, through adverse effects on the growth and development of organs and tissues (17, 18) .
Phthalates and bisphenol A are considered to be causative in the pathogenesis of diabetes type 2 and metabolic syndrome (1) (2) (3) (4) (5) . Also, in a short exposure study where volunteers were exposed to phthalates (9), a non-significant trend to metabolic syndrome was also found. In the present study, we only confirmed the relation of some phthalate metabolites to type 2 diabetes and not to other components of metabolic syndrome in the Czech population. The aim of this study was not to compare the organic pollutant level in subjects with and without metabolic syndrome. We have compared the urine level of bisphenol A and phthalates in subgroups of patients with metabolic syndrome comparing patients with and without three important components of metabolic syndrome (hypertension, dyslipidemia and diabetes).
Specifically, we found that only 4 phthalate metabolites − mono-n-butyl phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-oxohexyl) phthalate, and mono-(2-ethyl-5-carboxypentyl) phthalate were related to the presence of type 2 diabetes. Our data is supported by the NHANES survey where a relation of similar subgroup of phthalate metabolites to type 2 diabetes was found. For example, geometric mean of MnBP was 20.1 ng/mL in diabetics and 17.6 ng/mL in nondiabetics (19) . Median level of MnBP found in mothers from 17 European countries in the study DEMOCOPHES (20) was 22.0 μg/g creatinine. If the cause of high urine phthalates excretion would be only exogenous (e.g. diet, skin care), it would elevate the level of majority or all phthalate metabolites. The elevation of only 4 metabolites without any relation to BMI, hypertension, dyslipidemia, or age can be explained by some diabetes specific changes in metabolism of these 4 phthalate metabolites, especially in the liver resulting in their high circulating levels and a possible effect on beta cell function. Further modification of the effect of these 4 metabolites could be also mediated by low plasma testosterone levels (21) and inflammation (22) . Finally, endogenous production of some phthalates is linked to the presence of helicobacter pylori in stomach (23) and liver is the major source of phthalates metabolism, both organs to be affected by diabetes. Moreover, specific changes in liver metabolism were described in bisphenol A and can also be present in phthalates in some liver diseases, which are related to diabetes (24) . Thus, additional studies should be performed in higher number of diabetic patients with possible division to specific type 2 diabetes subgroups and their testosterone and other hormonal levels as well as the more precise assessment of beta cell dysfunction. It should be noted, that our study is not a longitudinal study and it cannot be used for any risk calculation including specific components of metabolic syndrome.
CONCLUSION
In the present study, we found a statistically significant correlation between phthalate metabolites, urine excretion and type 2 diabetes in a group of patients with metabolic syndrome. Urine levels of 4, but not of the other 11 phthalate metabolites were significantly higher in type 2 diabetes patients compared to those without diabetes. This influence was not related to BMI, dyslipidemia or hypertension. There was no significant difference in bisphenol A levels when comparing patients with and without diabetes, hypertension and dyslipidemia.
We concluded that high phthalate levels are in relation to type 2 diabetes. This study was not able to show if relation to beta cell dysfunction is causal. Further studies should be conducted to study in detail beta cell dysfunction in experimental and other models after the exposure of those metabolites. 
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